HomeTrialNCT06874010
🔬NCT06874010Phase 1Phase 2RECRUITING

A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia

Study Summary

The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment20 participants
Primary Completion
Lead SponsorDesign Therapeutics, Inc.
Data Retrieved2026-04-11 04:12:02.533348+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.